货号 | AF1189-SP |
别名 | CD323; JAM-2; JAM3; JAMC; JAM-CFLJ14529; junctional adhesion molecule 3JAM-3; junctional adhesion molecule C | 全称 | Junctional Adhesion Molecule C |
反应种属 | Human |
应用 | Western Blot(0.1 µg/mL) Flow Cytometry(2.5 µg/106cells) |
目标/特异性 | Detects human JAM‑C in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 75% cross-reactivity with recombinant mouse (rm) JAM-C is observed and less than 1% cross-reactivity with recombinant human JAM-1 and rmJAM-1 is observed. |
使用方法 | Western Blot: 0.1 µg/mL Flow Cytometry: 2.5 µg/106cells Neutralization: Measured by its ability to neutralize JAM‑C-mediated adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line. Fong, S. et al. (2002) J. Immunol. 168:1618. The Neutralization Dose (ND50) is typically 2‑8 µg/mL in the presence of 0.2 µg/mL Recombinant Human JAM‑B Fc Chimera. |
来源 | Polyclonal Goat IgG |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 83700 (Human); 83964 (Mouse) |
应用文献 | |
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. | |
纯化方式 | Antigen Affinity-purified |
免疫原 | Mouse myeloma cell line NS0-derived recombinant human JAM-C Val32-Asn241 (Ala149Pro) Accession # Q9BX67 |
内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
生物活性 | Human |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
背景 | The family of juctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial cells or epithelial cells. Some family members are also found on blood leukocytes and platelets. Human JAM-C cDNA predicts a 310 amino acid (aa) residue precursor protein with a putative 31 aa signal peptide, a 210 aa extracellular region containing two Ig domains, a 23 aa transmembrane domain and a 46 aa cytoplasmic domain containing a PDZ-binding motif and a PKC phosphorylation site (3, 4). Human JAM-C shares 86% aa sequence identity with its mouse homologue. It also shares approximately 36% and 32% aa sequence homology with human JAM-B and JAM-A, respectively (3‑5). Human JAM-C shows widespread tissue expression and the highest levels are found in the placenta, brain, kidney and heart. JAM-C is expressed on endothelial cells of high endothelial venules in human tonsil. It is also expressed on platelets, T-cells and NK cells (3‑5). Unlike other JAM family members, JAM-C forms only weak homotypic interactions. JAM-C binds to JAM-B to facilitate the interactions between JAM-B and the integrin alpha4beta1 (6). This heterotypic interaction between leukocyte JAM-C and endothelial JAM-B may play a role in regulating leukocyte transmigration (5). On platelets, JAM-C is a counter-receptor for the leukocyte integrin Mac-1(CD11b/CD18) (7). JAM-C has also been identified as a strong candidate gene for hypoplastic left heart syndrome (8). The nomenclature used for the JAM family proteins is confusing. VE-JAM has been referred to in the literature variously as JAM-B or JAM-C. Until further clarification, R&D Systems has adopted the nomenclature where both mouse and human VE-JAM are referred to as JAM-B. Under this system, JAM-C refers to the protein encoded by the gene localized to human chromosome 11. |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Cell Adhesion Mediated by JAM‑C and Neutralization by Human JAM‑C Antibody. Recombinant Human JAM-B/ VE-JAM Fc Chimera (Catalog # 1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G‑102‑C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM‑B Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Human JAM-C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1189). The ND50 is typically 2-8 µg/mL. |